Davis Polk advised the placement agents in connection with a private placement of shares of common stock of Applied Therapeutics, Inc. The aggregate proceeds of the private placement are approximately $20 million.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. Its lead product candidate is a novel aldose reductase inhibitor with broad systemic exposure and peripheral nerve permeability that it is developing for the treatment of diabetic cardiomyopathy.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Alain Kuyumjian and associate Amanda Rae Schwarzenbart. All members of the Davis Polk team are based in the New York office.

Copy link to share post